Supriya Lifescience gets Brazil approval for mental illness drug, files patent for heart & cholestrol medicine – CNBC TV18
| Company | Value | Change | %Change |
|---|
The company says it has become the first Indian outfit to secure approval from Brazil’s health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride. This allows Supriya Lifescience to expand its product portfolio across Brazil and the broader Latin America (LATAM) region.
Esketamine hydrochloride is used to treat mental illnesses and could find takers in the LATAM market. The company said ANVISA’s approval will enable it to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing.
Also Read: Supriya Lifescience embarks on key internal expansion, including R&D and distribution network
In another development, the company said it has filed a patent for a cost-effective manufacturing technique for Atorvastatin, a widely prescribed medication for managing cholesterol and preventing cardiovascular diseases.
“This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs,” the company said.
Satish Wagh, Executive Chairman and Whole Time Director of Supriya Lifescience said, “Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin.”
Also Read: Interview | The secret behind the tripling of profit for this Mumbai drug maker
“Our global presence is strengthened by the (Brazilian authority’s) approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil,” he added.
The company said it will continue its focus on innovation, regulatory compliance, and its mission to make high-quality healthcare accessible.
Shares of Supriya Lifescience Ltd ended at ₹783.10, up by ₹8.95, or 1.16% on the BSE.
